Lotrisone: Dual-Action Relief for Fungal and Inflammatory Skin Conditions
| Product dosage: 10 gr | |||
|---|---|---|---|
| Package (num) | Per tube | Price | Buy |
| 5 | $7.05 | $35.26 (0%) | 🛒 Add to cart |
| 6 | $6.45 | $42.31 $38.70 (9%) | 🛒 Add to cart |
| 7 | $6.02 | $49.36 $42.14 (15%) | 🛒 Add to cart |
| 8 | $5.70 | $56.42 $45.58 (19%) | 🛒 Add to cart |
| 9 | $5.45 | $63.47 $49.02 (23%) | 🛒 Add to cart |
| 10 | $5.25
Best per tube | $70.52 $52.46 (26%) | 🛒 Add to cart |
| Product dosage: 20 gr | |||
|---|---|---|---|
| Package (num) | Per tube | Price | Buy |
| 2 | $18.06 | $36.12 (0%) | 🛒 Add to cart |
| 4 | $15.70 | $72.24 $62.78 (13%) | 🛒 Add to cart |
| 8 | $14.30 | $144.48 $114.38 (21%) | 🛒 Add to cart |
| 16 | $13.65
Best per tube | $288.96 $218.44 (24%) | 🛒 Add to cart |
Synonyms | |||
Lotrisone combines the potent antifungal action of clotrimazole with the powerful anti-inflammatory properties of betamethasone dipropionate to comprehensively treat fungal skin infections accompanied by inflammation. This prescription medication offers targeted therapy for conditions where both infection and inflammatory response require simultaneous management. Its dual-mechanism approach addresses the root cause while providing symptomatic relief, making it a first-line choice for dermatologists treating complicated cutaneous mycoses. The formulation is specifically engineered for optimal skin penetration and sustained activity at the infection site.
Features
- Contains 1% clotrimazole USP and 0.05% betamethasone dipropionate USP
- Available in 15g and 45g tubes with white to off-white cream formulation
- Combines imidazole antifungal with mid-potency corticosteroid
- Specifically formulated for cutaneous application
- Stable emulsion base for consistent drug delivery
- Prescription-only medication requiring professional diagnosis
Benefits
- Provides simultaneous antifungal and anti-inflammatory action reducing treatment complexity
- Accelerates symptom relief including itching, redness, and scaling within days of initiation
- Comprehensive coverage against common dermatophytes including Trichophyton and Epidermophyton species
- Minimizes risk of secondary bacterial infections through inflammation control
- Convenient twice-daily application regimen supports patient compliance
- Prevents recurrence through complete eradication of fungal organisms
Common use
Lotrisone is primarily indicated for the topical treatment of the following dermatological conditions: tinea pedis (athlete’s foot), tinea cruris (jock itch), and tinea corporis (ringworm) caused by susceptible organisms including Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. It is specifically reserved for cases demonstrating significant inflammation, erythema, and pruritus where monotherapy with an antifungal agent would be insufficient. The medication is particularly effective in intertriginous areas where moisture and friction exacerbate both fungal growth and inflammatory response. Clinical studies demonstrate highest efficacy when used for the prescribed duration rather than as needed.
Dosage and direction
Apply a thin layer of Lotrisone cream to cover the affected area and approximately 1 inch of surrounding healthy skin twice daily, in the morning and evening. Gently massage until the cream is absorbed. Wash hands thoroughly after application unless treating hands. Treatment duration is typically 2 weeks for tinea corporis and tinea cruris, and 4 weeks for tinea pedis. Do not exceed these treatment durations due to corticosteroid component. Do not use occlusive dressings unless specifically directed by a physician. If no clinical improvement is observed after the designated treatment period, re-evaluation of diagnosis is necessary.
Precautions
Use Lotrisone with caution in patients with known sensitivity to any imidazole antifungal or corticosteroid. Avoid application to the face, groin, or axillae unless directed by a physician. Do not use in children under 12 years of age unless specifically prescribed. Prolonged use may lead to skin atrophy, striae, telangiectasia, and adrenal suppression. Monitor for signs of secondary infection. Discontinue if irritation develops. Patients with liver impairment should be monitored during extended therapy. Avoid contact with eyes and mucous membranes. Not recommended for use during pregnancy unless potential benefits outweigh risks.
Contraindications
Lotrisone is contraindicated in patients with hypersensitivity to clotrimazole, betamethasone dipropionate, or any component of the formulation. Should not be used for cutaneous viral infections (herpes simplex, varicella), tuberculous skin lesions, or fungal infections not responsive to imidazole derivatives. Contraindicated in patients with untreated bacterial skin infections. Not for ophthalmic use. Avoid in patients with widespread erythroderma or systemic fungal infections. Contraindicated in rosacea, perioral dermatitis, and acne vulgaris.
Possible side effects
Most common side effects include burning sensation (4%), pruritus (2%), and irritation (2%) at application site. Less frequently reported effects include erythema, peeling, blistering, swelling, and dryness. Systemic absorption may lead to corticosteroid-related effects including hypothalamic-pituitary-adrenal axis suppression, glucosuria, hypertension, and Cushing’s syndrome with prolonged use. Allergic contact dermatitis may occur. Secondary infection with bacteria or non-susceptible fungi may develop. Rare cases of pigmentation changes and hypertrichosis have been reported.
Drug interaction
No specific pharmacokinetic drug interactions have been documented with topical Lotrisone. However, concomitant use with other topical corticosteroids may increase systemic absorption and potential for adverse effects. Use with other topical products containing potentially irritating ingredients may increase local reactions. Systemic interactions are unlikely with proper topical application, but physicians should be aware of all medications the patient is taking.
Missed dose
Apply the missed dose as soon as remembered, unless it is almost time for the next scheduled application. Do not apply double the amount to make up for a missed dose. Maintain the regular application schedule. If multiple doses are missed, contact your healthcare provider for guidance on resuming treatment. Consistency in application is important for therapeutic efficacy.
Overdose
Topical overdose is unlikely but may occur with excessive application over large body surface areas, especially under occlusive dressings. Symptoms may include corticosteroid side effects such as thinning skin, striae, easy bruising, and systemic effects including hyperglycemia and adrenal suppression. Treatment involves discontinuation of the medication and supportive care. In case of accidental ingestion, seek immediate medical attention as systemic effects may include gastrointestinal irritation and potential corticosteroid toxicity.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F). Keep tube tightly closed when not in use. Protect from freezing and excessive heat. Do not store in bathroom where moisture levels fluctuate. Keep out of reach of children and pets. Discard any unused medication after the treatment course is completed. Do not transfer to other containers.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Lotrisone is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual results may vary. Always follow your physician’s instructions regarding use, dosage, and treatment duration. Do not use this medication for conditions other than those for which it was prescribed. Report any adverse reactions to your healthcare provider immediately.
Reviews
Clinical studies demonstrate Lotrisone achieves complete cure rates of 70-85% in inflammatory tinea infections when used as directed. Dermatologists report high satisfaction with its dual-action formulation for complicated cases. Patients note significant improvement in pruritus and erythema within 3-5 days of initiation. The combination therapy is preferred over sequential treatment for reducing overall treatment duration. Some reports indicate recurrence rates lower than antifungal monotherapy due to comprehensive anti-inflammatory action.